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Abstract
Background The aim of this study was to test the hypothesis
that urine levels of neutrophil gelatinase-associated lipocalin
(NGAL) and kidney injury molecule-1 (KIM-1) are en-
hanced in pediatric patients with hyperuricemia.
Methods The study included 88 children and adolescents (60
males, 28 females) with a median age of 16 (range 11–18.5)
years who had been referred to our department to rule out or
confirm hypertension. The subjects were divided into two
groups: the hyperuricemic (HU) group comprising 59 subjects
with hyperuricemia (defined as serum uric acid>4.8 and
>5.5 mg/dl in girls and boys, respectively) and the reference
group comprising 29 patients with normouricemia. Urine
NGAL and KIM-1 levels were evaluated using a commercial-
ly available kit.
Results Concentrations of the examined biomarkers [urine
NGAL, NGAL/creatinine (cr.) ratio, urine KIM-1, KIM-
1/cr. ratio] were increased in the HU group compared with
the reference group (p<0.01). There were positive correla-
tions between the serum uric acid and urine NGAL/cr. ratio
(R=0.67, p<0.001) and the urine KIM-1/cr. ratio (R=0.36,
p<0.001). In the multiple regression models, serum uric
acid, systolic blood pressure and cholesterol accounted for
more than 49 % of the variation in the NGAL/cr. ratio (R=
0.702, p<0.001). In the second model, serum uric acid,
gender, age and systolic blood pressure accounted for more
than 36 % of the variation in the KIM-1/cr. ratio (R=0.604,
p<0.001).
Conclusion We demonstrated that male, obese, hyperten-
sive adolescents with hyperuricemia have higher urine
NGAL and KIM-1 levels relative to a reference group with
normouricemia.
Keywords Hyperuricemia . Urine NGAL . Urine KIM-1 .
Hypertensive children and adolescents . Chronic kidney
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Introduction
The association between uric acid and chronic kidney disease
(CKD) has been known since the 1890s [1]. There is growing
evidence that CKD is associated with hyperuricemia, but
debate remains ongoing on whether renal impairment is due
to a direct nephrotoxic effect of uric acid or due to the
conditions caused by hyperuricemia. Recent experimental
studies have demonstrated that hyperuricemia causes hyper-
tension, afferent arteriolopathy, glomerular hypertrophy and
increased glomerular pressure, but also tubulointerstitial dam-
age [2–5]. Most studies have focused on uric acid-induced
endothelial dysfunction, oxidative stress and inflammation in
the kidney. The direct effects of uric acid on tubular cells have
not been studied in detail, although the recent study by Ryu et
al. [5] showed that uric acid, at physiological concentrations,
could induce phenotypic transition of renal tubular cells via
both a decreased synthesis and an enhanced degradation of E-
cadherin, thereby initiating epithelial–mesenchymal transition
of renal tubules and interstitial fibrosis.
Most of the recent evidence for a direct pathogenic effect of
hyperuricemia on the kidneys comes from animal studies.
However, studies in humans have been demonstrated that
hyperuricemia is associated with a decline in kidney function
and that allopurinol might slow this decline [6, 7]. In one
prospective study, patients with asymptomatic hyperuricemia
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treated with allopurinol showed significant improvement in
glomerular filtration rate (GFR) after 3 months of the therapy
[8]. Siu et al. reported that among patients with CKD treated
with allopurinol, 16 % progressed to end-stage renal disease
compared to 46 % in the control group [9].
Tubulointerstitial damage is characterized by inflamma-
tory cell infiltrates, loss of peritubular capillaries, tubular
atrophy and interstitial fibrosis. Tubular cells are important
players in the initiation and progression of renal damage.
Several tubular damage markers have recently been identi-
fied, and increased levels of these markers indicate tubular
damage or acute kidney injury after various nephrotoxic
insults, such as ischemia during cardiac surgery, sepsis and
the administration of contrast medium [10]. However, few
clinical studies have been performed in patients with CKD.
In addition, to the best of our knowledge the urinary levels
of tubular damage biomarkers in patients with hyperurice-
mia have not been studied.
Neutrophil gelatinase-associated lipocalin (NGAL) is a
promising emerging biomarker for early detection of kidney
injury. It is a member of the lipocalin family that is
expressed at low levels in several human tissues and rapidly
released from renal tubular cells in response to various
insults to the kidney [11, 12].
Another very well characterized urinary biomarker in
both experimental animals and humans with renal disease is
kidney injury molecule (KIM-1), which was isolated in
1998 by Ichimura et al. [13]. KIM-1 is a transmembrane
type 1 glycoprotein expressed at very low levels in the
normal kidney. It is markedly upregulated in proximal tu-
bules following renal ischemic or toxic injury in humans
and experimental animals [13, 14]. Cherian et al. found that
KIM-1 is a sensitive marker of early injury to tubular cells
[15]. The results of experimental and clinical studies show
that elevated urinary KIM-1 levels are strongly related to
tubular KIM-1 expression, indicating that KIM-1 is a very
promising biomarker for the presence of tubule–interstitial
pathology [16].
Whether tubular injury plays a role in mild hyperuricemia
remains unclear. Therefore, the aim of this study was to test
the hypothesis that urinary levels of NGAL and KIM-1 are
enhanced in pediatric patients with hyperuricemia.
Patients and methods
Informed consent was obtained from parents of all partici-
pants and children older than 16 years of age. The protocol
was approved by the Bioethics Committee of the Medical
University of Białystok in accordance with the Declaration
of Helsinki.
The study included 88 children and adolescents (60
males, 28 females) aged 11–18 years who were referred to
our unit (Department of Pediatrics and Nephrology, The
Medical University of Białystok, Poland) between May
2010 and September 2011 in order to confirm or rule out
hypertension. The majority of subjects were referred to our
department by general practitioners who had determined
that the patient had elevated causal blood pressure (BP).
The subjects were divided into two groups: a hyperuricemic
(HU) and normouricemic (reference) group, respectively.
The HU group comprised 59 children and adolescents (49
males, 10 females) with hyperuricemia, defined as serum
uric acid>4.8 mg/dl in girls and serum uric acid>5.5 mg/dl
in boys [17], confirmed primary hypertension or white-coat
hypertension. The reference group comprised 29 teenagers
(11 males, 18 females) with normouricemia and in whom at
the moment of examination hypertension was excluded on
the basis of ambulatory blood pressure monitoring (ABPM;
mean systolic and diastolic daytime and nighttime BP levels
of <90th percentile for age, sex and height and load systolic
and diastolic BP of <25 %). The participants in the reference
group had been full-term babies, with a normal birth weight,
and were not receiving any medication at the time of the
study. Family history of adolescents qualifying for this
group did not reveal gout or hypertension.
Inclusion criteria for the study for all participants were an
age of 11–18 years, normal clinical examination, normal renal
function and patients who were not receiving antihypertensive
or uric acid-reducing therapy. Exclusion criteria for entry into
the study were heart failure, diabetes mellitus, renal or hepatic
dysfunction, hematological disease, thrombocytopenia, sys-
temic inflammatory conditions and autoimmune diseases.
For all subjects, careful clinical histories were taken and
physical examinations were performed. Body weight and
height were measured using a balance beam scale and pediat-
ric wall-mounted stadiometer, respectively, and body mass
index (BMI) was calculated as weight (in kilograms) divided
by the square of height (meters squared). BMI Z-scores
reflecting the standard deviation score (SDS) for the age-
and gender-appropriate BMI distribution were calculated
using the formula: BMI Z-scores=(50 percentile for age +
gender)/½ × (50 percentile − 3 percentile for age and gender).
After 12 h of night fasting, between 7 and 8 a.m., urine
and blood samples were taken for the measurement of the
urine concentration of NGAL, KIM-1, creatinine (cr.) and
albuminuria, plasma C-reactive protein level and serum
creatinine, urea and uric acid levels, determination of the
lipid profile, and morphological profile of the peripheral
blood. Serum creatinine was determined by Jaffe reaction,
and uric acid was measured using the Hitachi apparatus
(Hitachi, Tokyo, Japan). The morphological characteristics
of the peripheral blood were assessed using the Beckman
Coulter MAXM AL flow cytometer (Beckman Coulter,
Fullerton, CA). Serum cholesterol, high-density lipid
(HDL)-cholesterol and triglycerides (TG) were determined
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by the enzymatic method using the Hitachi 912 chemistry
analyzer (Roche Diagnostics, Indianapolis, IN).
The 24-h urine albumin excretion rate (UAER) was ana-
lyzed using a radioimmunoassay method. Albuminuria was
considered as 24-h UAER >30 mg/24 h. Micro- and
macroalbuminuria were defined as 24-h UAER values of
30–300 and >300 mg/24 h, respectively. The estimated
glomerular filtration rate (eGFR) was calculated from the
Schwartz formula: eGFR ¼ 0:413  growth cmð Þ=serum
cr: mg=dlð Þ.
The concentration of urinary NGAL and KIM-1 was
measured using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit according to the manu-
facturer’s instructions. All specimens were diluted to obtain
the concentration for the optimal density according to the
instructions for the ELISA kit. Urine NGAL and urine KIM-
1 levels were expressed in nanograms per milliliter. Urine
creatinine concentration was used to normalize the NGAL
and KIM-1 measurements to account for the influence of
urinary dilution on its concentration. Finally, urine NGAL
and KIM-1 levels were expressed as the NGAL/cr. and
KIM-1/cr. ratio, respectively, in nanograms per milligram
of creatinine.
ABPM was performed using Spacelabs Healthcare
CardioNavigator (Spacelabs Healthcare, Issaquah, WA).
The monitors were programmed to measure BP every
15 min during daytime (0800–2200 hours) and every
30 min during nighttime (2200–08.00 hours); however,
these periods were corrected according to each patient’s
diary. Hypertension on the basis of ABPM was defined as
mean systolic or diastolic daytime or nighttime BP levels
that were≥95th percentile.
Statistical analysis
All continuous variables were tested for normal distribu-
tion using the Kolmogorov–Smirnov test with the
Lillefor’s correction and the Shapiro–Wilk test. As most
of the studied parameters were not normally distributed,
descriptive statistics were calculated as the median with
the interquartile range. The Mann–Whitney U test was
used to compare continuous variables, and the chi-square
(χ2) test with Yates’ correction was used to compare
categorical variables between two groups. Correlations
between uric acid, the NGAL/cr. ratio, the KIM-1/cr.
ratio and other studied variables were assessed using
Spearman’s correlation test. Two multiple linear regres-
sion models were created that included the NGAL/cr.
ratio and KIM-1/cr. ratio as dependent variables. Statisti-
cal significance was determined at p<0.05. All calcula-
tions were made using the Statistica ver. 10.0 program
(StatSoft Inc. Tulsa, OK) and the Stata/IC ver. 12.1
program (StataCorp LP, College Station, TX).
Results
The clinical and biochemical characteristics of the study
participants are listed in Table 1. The age of the HU patients
did not differ from that of the healthy controls (p=0.21).
Males were more frequently affected with hyperuricemia
than females. There were more males than females in the
HU group [49 (83.05%) vs. 10 (16.95 %), respectively],
whereas more females (n=18, 62.07 %) than males (n=11,
37.93 %) were found in the reference group (χ2 test 18.24:
p<0.01).
The body height, body weight and BMI of HU adoles-
cents were higher than those of adolescents in the reference
group (p<0.001), which can be partially explained by the
difference in number of males and females in each group.
However, the median BMI Z-score in the HU group was
2.12 (IQR 0.90–3.87) and higher than that found for the
reference group (p<0.001). Thirty-six subjects (61.01 %)
from the HU group were classified as overweight or obese.
Compared to the reference group, the HU patients had
increased serum creatinine (p<0.001) and urea levels
(p<0.01) and decreased eGFR (p<0.001). HU subjects also
had a higher cholesterol level and 24-h UAER than those in
the reference group (p<0.05 and p<0.001, respectively)
(Fig. 1). We found significant differences in the urine
NGAL and urine NGAL/cr. ratio, and in the urine KIM-1
and KIM-1/cr. ratio between HU patients and the reference
group. The median urine NGAL concentration (in ng/ml)
and NGAL/cr. ratio were 5.7- and 7.6-fold higher in HU
patients than in the reference group. There was a statistically
significant correlation (p<0.001, R=0.56) between urine
KIM-1/cr. and urine NGAL/cr. levels in the HU group.
Single regression analyses revealed that the serum uric
acid level was positively correlated with both the
NGAL/cr. and KIM-1/cr. ratios (R=0.67, p<0.001 and
R=0.37, p<0.001, respectively). The urine NGAL/cr. ra-
tio was also positively correlated with body weight
(R=0.32, p=0.002), BMI Z-score (R=0.37, p<0.001),
serum creatinine level (R=0.28, p=0.007), urea
(R=0.25, p=0.02), total cholesterol level (R=0.27,
p=0.01), 24-h UAER (R=0.39, p<0.001), systolic BP
(R=0.25, p=0.02) and diastolic BP (R=0.29, p=0.008) and
negatively correlatedwith eGFR (R=−0.26, p=0.01). The urine
KIM-1/cr. ratio was correlated positively with body weight (R=
0.27, p=0.01), BMI Z-score (R=0.3, p=0.004) and serum
creatinine levels (R=0.31, p=0.003) and negatively correlated
with eGFR (R=−0.29, p<0.01).
The factors that were found to have a significant corre-
lation with the urine NGAL/cr. ratio and KIM-1/cr. ratio in
the single regression analyses were used as explanatory
variables to create the multiple regression models. To reduce
the impact of multicollinearity we first removed a number of
correlated variables and then eliminated a few more non-
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significant (in the model) variables. This procedure resulted
in the creation of the two models shown in Tables 2 and
Table 3, respectively. In the first model (Table 2), the
remaining three parameters (serum uric acid, systolic BP
and cholesterol level) accounted for more than 49 % of the
variation in the NGAL/cr. ratio (R=0.702, p<0.001). In the
second model (Table 3), the remaining four parameters
(serum uric acid, gender, age and systolic BP) accounted
for more than 36 % of the variation in the KIM-1/cr. ratio
(R=0.604, p<0.001). It is interesting to note that male
gender correlated negatively with the KIM-1/cr. ratio in this
model.
Discussion
Our results demonstrate that male, obese, hypertensive ad-
olescents with hyperuricemia have higher urine NGAL and
KIM-1 levels than adolescents with normouricemia (the
reference group). Another important finding was the posi-
tive correlations between serum uric acid and the urine
NGAL/cr. and KIM-1/cr. ratios. Additionally, both urine
biomarkers correlated with parameters of renal function.
This correlation is in accordance with the results reported
by other authors who confirmed this relationship in immu-
noglobulin A (IgA) nephropathy, diabetic nephropathy and
autosomal dominant polycystic kidney disease [18–20].
Table 1 Clinical and biochemical characteristics of the group with hyperuricemia and the reference group (normouricemia)
Clinical and biochemical parameters HU (N=59) R (N=29) p value
Median (Q1;Q3) or proportion
Age (years) 16 (15; 17) 16 (15; 17) NS
Sex (male/female), n (% male) 49/10 (83.05 %) 11/18 (37.93 %) <0.001
Z-score BMI 2.12 (0.90; 3.87) −0.35 (−1.14; 0.46) <0.001
Serum uric acid (mg/dl) 6.7 (6.23; 7.31) 4.47 (3.8; 4.82) <0.001
Serum creatinine (mg/dl) 0.79 (0.69; 0.91) 0.56 (0.47; 0.68) <0.001
Urea (mg/dl) 25.5 (22; 29) 22 (19; 24) 0.002
Serum cholesterol (mg/dl) 183 (144; 201) 146 (139; 174) 0.02
TG/HDL ratio 2.52 (1.59; 3.68) 1.64 (1.22; 2.43) NS
eGFR (ml/min/1.73 m2) 90.10 (80.55; 103.57) 118.64 (106.2; 148.34) <0.001
24-h urine albumin excretion rate (UAER) mg/24-h 44.3 (8.64; 56.3) 9.5 (4.75; 14.3) <0.001
24 SBP (mmHg) 132 (122.5; 137) 118 (112; 122.5) <0.001
24 DBP (mmHg) 71 (66.5; 75) 66 (61.5; 70) <0.001
uNGAL (ng/ml) 8.54 (3.04; 18.55) 1.49 (0.81; 3.24) <0.001
NGAL/cr. (ng/mg cr.) 8.68 (2.08; 23.51) 1.14 (0.63; 2,58) <0.001
uKIM-1 (ng/ml) 1.3 (0,99; 2.1) 0.85 (0.38; 1.34) <0.001
KIM-1/cr. (ng/mg cr.) 1.26 (0.76; 1.87) 0.75 (0.46; 1.14) <0.001
Data in table are presented as the median with the interquartile range (IQR; Q1;Q3) given in parenthesis, unless stated otherwise
HU, Hyperuricemic group; R, reference group (normouricemia); BMI body mass index; TG, triglycerides; HDL, high-density lipoprotein; eGFR,
estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; uNGAL, urine neutrophil gelatinase-associated
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Fig. 1 Comparison of the urine neutrophil gelatinase-associated lipocalin/
creatinine (NGAL/cr.) ratio and the kidney injury molecule-1 (KIM-1)/cr.
ratio between patients with hyperuricemia and the reference group
1866 Pediatr Nephrol (2013) 28:1863–1869
However, the results of our study raise the challenging
question of the “chicken and egg” dilemma with regard to
uric acid and renal adverse outcomes. It is possible that the
uric acid is causing, or contributing to, subclinical kidney
disease.
The epidemic of metabolic syndrome, a major public
health problem, correlates with an excessive intake of fruc-
tose [21, 22]. Recent studies have demonstrated that urinary
uric acid excretion is remarkably reduced in fructose-fed
rats, resulting in hyperuricemia which in turn plays a path-
ogenic role in renal dysfunction and metabolic syndrome
[22, 23]. A large and growing body of evidence suggests
that hyperuricemia might be a risk factor for renal dysfunc-
tion [24]. Hu et al. [25] demonstrated that in fructose-fed
rats, not only was there a reduction in urine uric acid and
creatinine excretion, but there was also a significant eleva-
tion of serum creatinine and blood urea nitrogen levels,
indicating renal dysfunction.
The molecular mechanism for fructose-induced hyperuri-
cemia was proposed by Le et al. [26]. These authors dem-
onstrated that SLC22A, one of classic polyspecific urate
transporters in the proximal kidney tubule which take part
in the reabsorption and secretion of renal uric acid, plays a
pivotal role in renal dysfunction. The organic cation trans-
porters OCT1 (SLC22A1) and OCT2 (SLC22A2) in the
proximal renal tubules cooperate with each other in the
excretion of organic cations from the kidneys. Decreased
expression level of rOCT2 in the rat kidney was shown in
ischemia- and reperfusion-induced acute kidney injury [27]
and in hyperuricemia [28]. The reduction of renal expres-
sion of other t ransporters was also reported in
streptozotocin-induced diabetic rats [29] and nephrotoxicity
[30].
The mechanism of HU nephropathy is still a matter of
debate. Previous studies have demonstrated uric acid-
induced endothelial dysfunction and local inflammation in
the kidney as major mechanisms of renal disease [2, 7, 24,
31, 32]. However, the novel finding of Ryu et al. [5]
strongly suggest that uric acid also has direct effects on
renal tubules. In this study, the authors observed phenotypic
transition of the renal tubules before the development of
renal dysfunction and significant tubulointerstitial fibrosis in
hyperuricemic rats, which was ameliorated by uric acid-
lowering therapy. The study by Han et al. [33] showed uric
acid-induced inhibition of tubular cell proliferation in vitro.
Another study demonstrated an upregulation of ERK, BAX
and α-SMA in HK-2 cells exposed to uric acid using SILAC
coupled to liquid chromatography-mass spectrometry [34].
In our study we confirmed an increased urine level of
tubule damage markers in male adolescents with hyperurice-
mia. It is worth noting that the urine NGAL/cr. ratio in patients
with hyperuricemia was about sevenfold higher than that in
the normouricemic subjects in the reference group, while the
urine KIM-1/cr. ratio exceeded the values of reference group
by only twofold. It is difficult to explain this result because we
found a statistically significant correlation between the urine
NGAL/cr. and KIM-1/cr. ratios. One possible explanation
might be that the urine KIM-1/cr. ratio correlates with gender
and is lower in males; in our study, there was a preponderance
of males in the HU group.
A review of the literature found no data on the associa-
tion between serum uric acid and the urine NGAL/cr. or
KIM-1/cr. ratios. Urine NGAL has been studied extensively
in preclinical and clinical models and has been found to be a
potential biomarker of a number of pathologic conditions,
including acute kidney injury, diabetic nephropathy, IgA
nephropathy, contrast nephropathy, and a useful tool in
disease monitoring in other renal diseases, such as delayed
graft function, lupus nephritis, IgA nephropathy and poly-
cystic disease [20, 35–37].
In recent years, there has been an increasing amount of data
published on role of KIM-1 in kidney injury. KIM-1 appears
to play a role in the pathogenesis of tubular cell damage and
repair in experimental and human kidney disease. It has been
found to be upregulated after nephrotoxicant-induced renal
injury [38] and in the murine model of polycystic kidney
Table 2 Multiple linear regres-
sion analysis of the NGAL/cre-
atinine ratio
Variables Coefficient Standard error 95 % Confidence interval p value
Serum uric acid 7.24 1.014 (5.22; 9.27) <0.001
Systolic blood pressure −0.137 0.0478 (−0.233; −0.042) 0.005
Cholesterol 0.0996 0.0399 (0.0201; 0.1792) 0.02
Table 3 Multiple linear regres-
sion analysis of the KIM-1/cre-
atinine ratio
Variables Coefficient Standard error 95 % Confidence interval p value
Serum uric acid 0.464 0.0799 (0.305; 0.624) <0.001
Gender −0.729 0.242 (−1.212; −0.246) 0.004
Age 0.119 0.0609 (−0.0021; 0.2405) 0.05
Systolic blood pressure −0.0103 0.0039 (−0.018; -0.0025) 0.01
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disease [39] and human renal carcinoma [40]. Vaidya et al.
[41] obtained interesting results which demonstrated that
KIM-1 was increased 1 day after ischemia–reperfusion injury
in rats, before a rise in proteinuria or plasma creatinine could
be observed, indicating that KIM-1 is a very early, specific
biomarker of acute kidney injury. As already mentioned, very
little information is currently available in the literature on the
influence of uric acid on urine KIM-1 levels. Nepal et al. [42]
reported one case of acute urate nephropathy and one case of
chronic urate nephropathy in two pediatric patients. These
authors demonstrated the upregulation of KIM-1 in proximal
tubular cells, which implicates a role for KIM-1 in proximal
tubular injury in urate nephropathy. This observation was
confirmed in our study. It is also worth mentioning that some
hyperuricemic patients had first or second degree CKD based
on a decreased eGFR, elevated levels of serum creatinine and
albuminuria. We also found statistically significant correla-
tions between both NGAL and KIM-1 and parameters or renal
function. These results lead us to consider that elevations in
NGAL and KIM-1 levels may reflect the degree of CKD due
to hyperuricemia. However, this notion must be confirmed in
larger group of patients.
Another point which should be discussed is the positive
correlation between the NGAL/cr. ratio and components of
metabolic syndrome. In our study, most of the HU patients
(67.79 %) were hypertensive, with 61.01 % being over-
weight or obese. Our finding of a correlation between
NGAL and BP values is in agreement with those reported
by Eirin et al. [43] who showed that urinary levels of NGAL
were elevated in both essential hypertension and renovascu-
lar hypertension. It seems possible that these results were
due to ongoing kidney and systemic inflammation and is-
chemia in hypertensive patients. These findings further sup-
port the notion of Blumczynski et al. [44] who considered
that in children with primary hypertension, increased serum
and urine NGAL may reflect kidney injury earlier than
typical markers of hypertensive nephropathy. Recent evi-
dence suggests that NGAL may also be involved in chronic
vascular remodeling during the development of atheroscle-
rosis [45]. In our study we found a significant correlation
between NGAL and serum cholesterol level, but not with
TG level and the TG/HDL ratio (which is considered to be a
marker of atherosclerosis). In reviewing the literature, we
found no data on the association between urine NGAL and
BMI or obesity; therefore, further research should be
conducted to investigate this relationship.
We also found a positive correlation between the urine
KIM-1/cr. ratio and the BMI Z-score. However, we were
unable to obtain any data on this relationship in the literature.
The findings of this study suggest that urine NGAL rather
than urine KIM-1 may serve as an early marker of tubular
damage due to hyperuricemia. However, this research may
only serve as a base for future studies.
Finally, a number of important limitations to this study
need to be considered. First, this study is limited by its
relatively small study population and cross-sectional nature.
Secondly, the reference group was not a group of healthy
teenagers, but a group of patients with normouricemia, in
whom hypertension was not confirmed in 24-h ABPM, so
they were considered to be the white coat hypertension
group. Thirdly, there were the evident differences between
the study groups, with the HU group consisting of predom-
inantly of adolescent males mainly with a high BMI Z-score
and reference group including relatively more females with
white coat hypertension.
Acknowledgments This study was supported by a research grant
from the Medical University of Bialystok (No 123-41765 L).
Conflict of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Feig DI (2009) Uric acid: a novel mediator and marker of risk in
chronic kidney disease? Curr Opin Nephrol Hypertens 18:526–530
2. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH,
Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ
(2002) Hyperuricemia induces a primary renal arteriolopathy in
rats by a blood pressure-independent mechanism. Am J Physiol
Renal Physiol 282:F991–F997
3. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto
V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-
Acosta J (2005) Mild hyperuricemia induces vasoconstriction
and maintains glomerular hypertension in normal and remnant
kidney rats. Kidney Int 67:237–247
4. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S,
Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J,
Johnson RJ (2003) Hyperuricemia causes glomerular hypertrophy
in the rat. Am J Nephrol 23:2–7
5. Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ,
Kang DH (2013) Uric acid- induced phenotypic transition of renal
tubular cells as a novel mechanism of chronic kidney disease. Am
J Physiol Renal Physiol 304:F471–F480
6. Ji B, Zhang S, Gong L, Wang Z, Ren W, Li Q, Li R (2013) The risk
factors of mild decline in estimated glomerular filtration rate in a
community-based polulation. Clin Biochem. doi: 10.1016/
j.clinbiochem.2013.01.011
7. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascu-
lar risk. N Engl J Med 359:1811–1821
8. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz
E, Akcay A, Yigitoglu R, Covic A (2007) Effect of treatment of
hyperuricemia with allopurinol on blood pressure, creatinine
clearence, and proteinuria in patients with normal renal functions.
Int Urol Nephrol 39:1227–1233
9. Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol
in slowing the progression of renal disease through its ability to
lower serum uric acid level. Am J Kidney Dis 47:51–59
1868 Pediatr Nephrol (2013) 28:1863–1869
10. Bagshaw SM, Bellomo R (2007) Early diagnosis of acute kidney
injury. Curr Opin Crit Care 13:638–644
11. Venge P, Carlson M, Fredens K, Garcia R (1999) The 40 kD-
protein. A new protein isolated from the secondary granules of
human neutrophils: Joint International Conference on Leukocyte
Biology. J Leukocyte Biol 1:28
12. Allen RA, Erickson RW, Jesaitis AJ (1989) Identification of a
human neutrophil protein of Mr 24 000 that binds N-formyl
peptides: co-sedimentation with specific granules. Biochim
Biophys Acta 991:123–133
13. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL,
Sanicola M (1998) Kidney injury molecule-1 (KIM-1), a putative
epithelial cell adhesion molecule containing a novel immunoglob-
ulin domain, is up-regulated in renal cells after injury. J Biol Chem
273:4135–4142
14. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV
(2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker for
human renal proximal tubule injury. Kidney Int 62:237–244
15. Cherian S, Crompton CH (2005) Partial hypoxanthine-guanine
phosphoribosyltransferase deficiency presenting as acute renal
failure. Pediatr Nephrol 20:1811–1813
16. Lock EA (2010) Sensitive and early markers of renal injury: where
are we and what is the way forward? Toxicol Sci 116:1–4
17. Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary
hypertension. Hypertension 42:247–252
18. Xu PC, Zhang JJ, Chen M, Lv JC, Liu G, Zou WZ, Zhang H, Zhao
MH (2011) Urinary kidney injury molecule-1 in patients with IgA
nephropathy is closely associated with disease severity. Nephrol
Dial Transplant 26:3229–3236
19. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY (2009) Changes
of serum and urine neutrophil gelatinase-associated lipocalin in type-
2 diabetic patients with nephropathy: one year observational follow-
up study. Endocrine 36:45–51
20. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina
N, Buemi M (2007) Neutrophil gelatinase-associated lipocalin in
patients with autosomal-dominant polycystic kidney disease. Am J
Nephrol 27:373–378
21. Miatello R, Vázquez M, Renna N, Cruzado M, Zumino AP, Risler N
(2005) Chronic administration of resveratrol prevents biochemical
cardiovascula changes in fructose-fed rats. Am J Hypertens 18:864–870
22. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova
O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM,
Johnson RJ (2006) A causal role for uric acid in fructose-induced
metabolic syndrome. Am J Physiol Renal Physiol 290:F625–F631
23. Gersch MS, Mu W, Cirillo P, Reungjui S, Zhang L, Roncal C,
Austin YY, Johnson RJ, Nakagawa T (2007) Fructose, but not
dextrose, accelerates the progression of chronic kidney disease.
Am J Physiol Renal Physiol 293:F1256–F1261
24. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M,
Truong L, Harris R, Johnson RJ (2002) A role for uric acid in the
progression of renal disease. J Am Soc Nephrol 13:2888–2897
25. Hu QH, Wang C, Li JM, Zhang DM, Kong LD (2009) Allopurinol,
rutin, and quercetin attenuate hyperuricemia and renal dysfunction
in rats induced by fructose intake: renal organic ion transporter
involvement. Am J Physiol Renal Physiol 297:F1080–F1091
26. Le MT, Shafiu M, Mu W, Johnson RJ (2008) SLC2A9-A fructose
transporter identified as a novel uric acid transporter. Nephrol Dial
Transplant 23:2746–2749
27. Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A,
Nonoguchi H, Kohda Y, Tomita K, Inui K, Saito H (2008) Altered
pharmacokinetics of cationic drugs caused by down-regulation of
renal rat organic cation transporter 2 (Slc22a2) and rat multidrug
and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced
acute kidney injury. Drug Metab Dispos 36:649–654
28. Habu Y, Yano I, Okuda M, Fukatsu A, Inui K (2005) Restored
expression and activity of organic ion transporters rOAT1, rOAT3
and rOCT2 after hyperuricemia in the rat kidney. Biochem
Pharmacol 69:993–999
29. Grover B, Buckley D, Buckley AR, Cacini W (2004) Reduced
expression of organic cation transporters rOCT1 and rOCT2 in
experimental diabetes. J Pharmacol Exp Ther 308:949–956
30. Rizwan AN, Burckhardt G (2007) Organic anion transporters of
the SLC22 family: biopharmaceutical, physiological, and patho-
logical roles. Pharm Res 24:450–470
31. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck
ML (2008) Uric acid stimulates vascular smooth muscle cell pro-
liferation and oxidative stress via the vascular renin-angiotensin
system. J Hypertens 26:269–275
32. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH (2010)
Oxidative stress with an activation of the renin-angiotensin
system in human vascular endothelial cells as a novel mecha-
nism of uric acid-induced endothelial dysfunction. J Hypertens
28:1234–1242
33. Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M (2007) Uric
acid inhibits renal proximal tubule cell proliferation via at least two
signaling pathways involving PKC, MAPK, cPLA2, and NF-
kappaB. Am J Physiol Renal Physiol 292:F373–F381
34. Quan H, Peng X, Liu S, Bo F, Yang L, Huang Z, Li H, Chen X, Di
W (2011) Differentially expressed protein profile of renal tubule
cell stimulated by elevated uric acid using SILAC coupled to LC-
MS. Cell Physiol Biochem 27:91–98
35. Ding H, He Y, Li K, Yang J, Li X, Lu R, Gao W (2007) Urinary
neutrophil gelatinase- associated lipocalin (NGAL)) is an early
biomarker for renal tubulointerstitial injury in IgA nephropathy.
Clin Immunol 123:227–234
36. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom
A, Mishra J, Devarajan P (2006) Urinary neutrophil gelatinase-
associated lipocalin as a biomarker of nephritis in childhood-onset
systemic lupus erythematosus. Arthritis Rheum 54:2577–2584
37. Wasilewska A, Taranta-Janusz K, Dębek W, Zoch-Zwierz W,
Kuroczycka-Saniutycz E (2011) KIM-1 and NGAL: new markers
of obstructive nephropathy. Pediatr Nephrol 26:579–586
38. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV (2004)
Kidney injury molecule-1: a tissue and urinary biomarker for
nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol
286:F552–F563
39. Kuehn EW, Park KM, Somlo S, Bonventre JV (2002) Kidney
injury molecule-1 expression in murine polycystic kidney disease.
Am J Physiol Renal Physiol 283:F1326–F1336
40. Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern
FJ, Thadhani R, Bonventre JV (2005) Human kidney injury
molecule-1 is a tissue and urinary tumor marker of renal cell
carcinoma. J Am Soc Nephrol 16:1126–1134
41. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV
(2006) Urinary kidney injury molecule-1: a sensitive quantitative
biomarker for early detection of kidney tubular injury. Am J
Physiol Renal Physiol 290:F517–F529
42. Nepal M, Bock GH, Sehic AM, Schultz MF, Zhang PL (2008)
Kidney injury molecule-1 expression identifies proximal tubular
injury in urate nephropathy. Ann Clin Lab Sci 38:210–214
43. Eirin A, Gloviczki ML, Tang H, Rule AD, Woollard JR, Lerman
A, Textor SC, Lerman LO (2012) Chronic renovascular hyperten-
sion is associated with elevated levels of neutrophil gelatinase-
associated lipocalin. Nephrol Dial Transplant 27:4153–4161
44. Blumczynski A, Sołtysiak J, Lipkowska K, Silska M, Poprawska
A, Musielak A, Zaniew M, Zachwieja J (2012) Hypertensive
nephropathy in children—do we diagnose early enough? Blood
Press 21:233–239
45. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup
J, Thorén P, Hansson GK (2006) Expression of neutrophil
gelatinase-associated lipocalin in atherosclerosis and myocardial
infarction. Arterioscler Thromb Vasc Biol 26:136–142
Pediatr Nephrol (2013) 28:1863–1869 1869
